Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma

Overview of attention for article published in Frontiers in oncology, December 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 2 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 24,846 followers.

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma https://t.co/nRYw4FzwVL https://t.co/Yg5gw3eVa9

23 Dec 2022

Reply Repost Favourite

RT @FrontOncology: New research: Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive…

23 Dec 2022

Reply Repost Favourite

New research: Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma: Background Muscle invasive bladder urothelium carcinoma is a common urinary tract tumor. With… https://t.

23 Dec 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.